Functional and Structural Neural Changes in Obsessive-compulsive Disorder after Pharmacotherapy

Author(s): Murad Atmaca*.

Journal Name: Current Neuropharmacology

Volume 17 , Issue 8 , 2019

Become EABM
Become Reviewer

Graphical Abstract:


Abstract:

Obsessive-compulsive disorder (OCD) is an important disorder which is disturbing the quality of life and is characterized by repetitive thoughts and behaviors, now in a different category in the Diagnostic and Statistical Manual for Mental Disorders Fifth Edition (DSM 5). Neuroimaging investigations are very useful to reveal a neurobiological model of the OCD. Studies conducted in the last quarter century have shown clear results and revealed that specific cortico-subcortical circuits could be involved in the occurrence of OCD symptomatology. These neuroimaging studies pointed out some important findings for OCD patients. Our present information implicates some problems in some cortico-subcortical in the pathophysiology of OCD. In the present paper, final information on the neuroanatomy and neurochemistry of OCD was reviewed, revising the effects of anti-obsessional drugs on the structural and functional neuroimaging studies. As can be seen in the review, drug treatments can generally affect the brain structurally and functionally, suggesting that brain of OCD tends to neuroplasticity. However, it is not clear that these effects of pharmacotherapy are related to anti-obsessional drugs per se or impact on the improvement of the disorder.

Keywords: OCD, functional, structural, pharmacotherapy, neural, changes.

[1]
American Psychiatric Association. Diagnostic and statistical manual of mental disorders; 5th ed; (DSM-5): Arlington, VA, 2013.
[2]
Weisman, M.M.; Bland, R.C.; Canino, G.J.; Greenwald, S.; Hwu, H.G.; Lee, C.K.; Wittchen, H.U. The cross-national epidemiology of obsessive-compulsive disorder. J. Clin. Psychiatry, 1994, 55, 5-10.
[3]
Eichstedt, J.A.; Arnold, S.L. Childhood-onset obsessive-compulsive disorder: A tic-related subtype of OCD? Clin. Psychol. Rev., 2001, 21(1), 137-157. [http://dx.doi.org/10.1016/S0272-7358(99)00044-6]. [PMID: 11148894].
[4]
Geller, P.A.; Klier, C.M.; Neugebauer, R. Anxiety disorders following miscarriage. J. Clin. Psychiatry, 2001, 62(6), 432-438. [http://dx.doi.org/10.4088/JCP.v62n0606]. [PMID: 11465520].
[5]
Saxena, S.; Bota, R.G.; Brody, A.L. Brain-behavior relationships in obsessive-compulsive disorder. Semin. Clin. Neuropsychiatry, 2001, 6(2), 82-101. [http://dx.doi.org/10.1053/scnp.2001.21833]. [PMID: 11296309].
[6]
Scarone, S.; Colombo, C.; Livian, S.; Abbruzzese, M.; Ronchi, P.; Locatelli, M.; Smeraldi, E. Increased right caudate nucleus size in obsessive-compulsive disorder: detection with magnetic resonance imaging. Psychiatry Res. Neuroimaging, 1992, 45, 115-121. [http://dx.doi.org/10.1016/0925-4927(92)90005-O].
[7]
Robinson, D.; Wu, H.; Munne, R.A.; Ashtari, M.; Alvir, J.M.; Lerner, G.; Koreen, A.; Cole, K.; Bogerts, B. Reduced caudate nucleus volume in obsessive-compulsive disorder. Arch. Gen. Psychiatry, 1995, 52(5), 393-398. [http://dx.doi.org/10.1001/archpsyc. 1995.03950170067009]. [PMID: 7726720].
[8]
Szeszko, P.R.; Robinson, D.; Alvir, J.M.; Bilder, R.M.; Lencz, T.; Ashtari, M.; Wu, H.; Bogerts, B. Orbital frontal and amygdala volume reductions in obsessive-compulsive disorder. Arch. Gen. Psychiatry, 1999, 56(10), 913-919. [http://dx.doi.org/10.1001/archpsyc. 56.10.913]. [PMID: 10530633].
[9]
Khalsa, S.S.; Schiffman, J.E.; Bystritsky, A. Treatment-resistant OCD: options beyond first-line medications. Curr. Psychiatr., 2011, 10, 45.
[10]
Ninan, P.T.; Koran, L.M.; Kiev, A. High-dose sertraline strategy for nonresponders to acute treatment for obsessive-compulsive disorder: A multicenter double-blind trial. Year Book of Psychiatry & Applied Mental Health, 2007, 2007, 242-243. [http://dx.doi. org/10.1016/S0084-3970(08)70541-3].
[11]
Dell’osso, B.; Mundo, E.; Marazziti, D.; Altamura, A.C. Switching from serotonin reuptake inhibitors to duloxetine in patients with resistant obsessive compulsive disorder: a case series. J. Psychopharmacol. (Oxford), 2008, 22(2), 210-213. [http://dx.doi.org/ 10.1177/0269881107079865]. [PMID: 18208931].
[12]
Pallanti, S.; Quercioli, L.; Paiva, R.S.; Koran, L.M. Citalopram for treatment-resistant obsessive-compulsive disorder. Eur. Psychiatry, 1999, 14(2), 101-106. [http://dx.doi.org/10.1016/S0924-9338(99) 80725-1]. [PMID: 10572334].
[13]
Ravizza, L.; Barzega, G.; Bellino, S.; Bogetto, F.; Maina, G. Therapeutic effect and safety of adjunctive risperidone in refractory obsessive-compulsive disorder (OCD). Psychopharmacol. Bull., 1996, 32(4), 677-682. [PMID: 8993091].
[14]
Fallon, B.A.; Liebowitz, M.R.; Campeas, R. Intravenous clomipramine for obsessive-compulsive disorder refractory to oral clomipramine: A placebo-controlled study. Year Book of Psychiatry and Applied Mental Health, 2000, 2000, 345-346.
[15]
Dannon, P.N.; Sasson, Y.; Hirschmann, S.; Iancu, I.; Grunhaus, L.J.; Zohar, J. Pindolol augmentation in treatment-resistant obsessive compulsive disorder: a double-blind placebo controlled trial. Eur. Neuropsychopharmacol., 2000, 10(3), 165-169. [http://dx. doi.org/10.1016/S0924-977X(00)00065-1]. [PMID: 10793318].
[16]
Hewlett, W.A.; Schmid, S.P.; Salomon, R.M. Pilot trial of ondansetron in the treatment of 8 patients with obsessive-compulsive disorder. J. Clin. Psychiatry, 2003, 64(9), 1025-1030. [http://dx.doi.org/ 10.4088/JCP.v64n0907]. [PMID: 14628977].
[17]
Saxena, S.; Brody, A.L.; Maidment, K.M.; Dunkin, J.J.; Colgan, M.; Alborzian, S.; Phelps, M.E.; Baxter, L.R., Jr Localized orbitofrontal and subcortical metabolic changes and predictors of response to paroxetine treatment in obsessive-compulsive disorder. Neuropsychopharmacology, 1999, 21(6), 683-693. [http://dx. doi.org/10.1016/S0893-133X(99)00082-2]. [PMID: 10633474].
[18]
Atmaca, M.; Yildirim, H.; Ozdemir, H.; Tezcan, E.; Poyraz, A.K. Volumetric MRI study of key brain regions implicated in obsessive-compulsive disorder. Prog. Neuropsychopharmacol. Biol. Psychiatry, 2007, 31(1), 46-52. [http://dx.doi.org/10.1016/j.pnpbp. 2006.06.008]. [PMID: 16859819].
[19]
Gilbert, A.R.; Moore, G.J.; Keshavan, M.S.; Paulson, L.A.; Narula, V.; Mac Master, F.P.; Stewart, C.M.; Rosenberg, D.R. Decrease in thalamic volumes of pediatric patients with obsessive-compulsive disorder who are taking paroxetine. Arch. Gen. Psychiatry, 2000, 57(5), 449-456. [http://dx.doi.org/10.1001/archpsyc.57.5.449]. [PMID: 10807485].
[20]
Hoexter, M.Q.; de Souza Duran, F.L.; D’Alcante, C.C.; Dougherty, D.D.; Shavitt, R.G.; Lopes, A.C.; Diniz, J.B.; Deckersbach, T.; Batistuzzo, M.C.; Bressan, R.A.; Miguel, E.C.; Busatto, G.F. Gray matter volumes in obsessive-compulsive disorder before and after fluoxetine or cognitive-behavior therapy: a randomized clinical trial. Neuropsychopharmacology, 2012, 37(3), 734-745. [http://dx. doi.org/10.1038/npp.2011.250]. [PMID: 22030709].
[21]
Lázaro, L.; Bargalló, N.; Castro-Fornieles, J.; Falcón, C.; Andrés, S.; Calvo, R.; Junqué, C. Brain changes in children and adolescents with obsessive-compulsive disorder before and after treatment: a voxel-based morphometric MRI study. Psychiatry Res., 2009, 172(2), 140-146. [http://dx.doi.org/10.1016/j.pscychresns.2008.12. 007]. [PMID: 19321314].
[22]
Atmaca, M.; Mermi, O.; Yildirim, H.; Gurok, M.G. Orbito-frontal cortex and thalamus volumes in obsessive-compulsive disorder before and after pharmacotherapy. Brain Imaging Behav., 2016, 10(3), 669-674. [http://dx.doi.org/10.1007/s11682-015-9426-0]. [PMID: 26311393].
[23]
Atmaca, M.; Yildirim, H.; Mermi, O.; Gurok, M.G. Effects of anti-obsessional treatment on pituitary volumes in obsessive-compulsive disorder. Psychiatr. Danub., 2016, 28(1), 58-62. [PMID: 26938823].
[24]
Yun, J.Y.; Jang, J.H.; Kim, S.N.; Jung, W.H.; Kwon, J.S. Neural correlates of response to pharmacotherapy in obsessive-compulsive disorder: Individualized cortical morphology-based structural covariance. Prog. Neuropsychopharmacol. Biol. Psychiatry, 2015, 63(63), 126-133. [http://dx.doi.org/10.1016/j.pnpbp.2015.06.009]. [PMID: 26116795].
[25]
Björgvinsson, T.; Hart, J.; Heffelfinger, S. Obsessive-compulsive disorder: update on assessment and treatment. J. Psychiatr. Pract., 2007, 13(6), 362-372. [http://dx.doi.org/10.1097/01.pra.0000300122. 76322.ad]. [PMID: 18032981].
[26]
Brem, S.; Hauser, T.U.; Iannaccone, R.; Brandeis, D.; Drechsler, R.; Walitza, S. Neuroimaging of cognitive brain function in paediatric obsessive compulsive disorder: A review of literature and preliminary meta-analysis. J. Neural Transm. (Vienna), 2012, 119(11), 1425-1448. [http://dx.doi.org/10.1007/s00702-012-0813-z]. [PMID: 22678698].
[27]
Chamberlain, S.R.; Menzies, L.; Hampshire, A.; Suckling, J.; Fineberg, N.A.; del Campo, N.; Aitken, M.; Craig, K.; Owen, A.M.; Bullmore, E.T.; Robbins, T.W.; Sahakian, B.J. Orbitofrontal dysfunction in patients with obsessive-compulsive disorder and their unaffected relatives. Science, 2008, 321(5887), 421-422. [http://dx.doi.org/10.1126/science.1154433]. [PMID: 18635808].
[28]
Rotge, J.Y.; Guehl, D.; Dilharreguy, B.; Cuny, E.; Tignol, J.; Bioulac, B.; Allard, M.; Burbaud, P.; Aouizerate, B. Provocation of obsessive-compulsive symptoms: A quantitative voxel-based meta-analysis of functional neuroimaging studies. J. Psychiatry Neurosci., 2008, 33(5), 405-412. [PMID: 18787662].
[29]
Menzies, L.; Chamberlain, S.R.; Laird, A.R.; Thelen, S.M.; Sahakian, B.J.; Bullmore, E.T. Integrating evidence from neuroimaging and neuropsychological studies of obsessive-compulsive disorder: the orbitofronto-striatal model revisited. Neurosci. Biobehav. Rev., 2008, 32(3), 525-549. [http://dx.doi.org/10.1016/j.neubiorev. 2007.09.005]. [PMID: 18061263].
[30]
Bhikram, T.P.; Farb, N.A.S.; Ravindran, L.N.; Papadopoulos, Y.G.; Conn, D.K.; Pollock, B.G.; Ravindran, A.V. The effect of intravenous citalopram on the neural substrates of obsessive-compulsive disorder. J. Neuropsychiatry Clin. Neurosci., 2016, 28(3), 243-247. [http://dx.doi.org/10.1176/appi.neuropsych.15090213]. [PMID: 27019066].
[31]
Jang, J.H.; Kwon, J.S.; Jang, D.P.; Moon, W.J.; Lee, J.M.; Ha, T.H.; Chung, E.C.; Kim, I.Y.; Kim, S.I. A proton MRSI study of brain N-acetylaspartate level after 12 weeks of citalopram treatment in drug-naive patients with obsessive-compulsive disorder. Am. J. Psychiatry, 2006, 163(7), 1202-1207. [http://dx.doi.org/ 10.1176/ajp.2006.163.7.1202]. [PMID: 16816225].
[32]
Han, J.Y.; Kang, D.H.; Gu, B.M.; Jung, W.H.; Choi, J.S.; Choi, C.H.; Jang, J.H.; Kwon, J.S. Altered brain activation in ventral frontal-striatal regions following a 16-week pharmacotherapy in unmedicated obsessive-compulsive disorder. J. Korean Med. Sci., 2011, 26(5), 665-674. [http://dx.doi.org/10.3346/jkms.2011.26.5. 665]. [PMID: 21532859].
[33]
Yoo, S.Y.; Jang, J.H.; Shin, Y.W.; Kim, D.J.; Park, H.J.; Moon, W.J.; Chung, E.C.; Lee, J.M.; Kim, I.Y.; Kim, S.I.; Kwon, J.S. White matter abnormalities in drug-naïve patients with obsessive-compulsive disorder: a diffusion tensor study before and after citalopram treatment. Acta Psychiatr. Scand., 2007, 116(3), 211-219. [http://dx.doi.org/10.1111/j.1600-0447.2007.01046.x]. [PMID: 17655563].
[34]
Kamini, L. Ho, Piana.; Harold, J.G.M.; van, Megen.; Nick, F. Ramsey.; Rene, Mandla.; Peter P, van Rijkb.; Wynne H.J.; Herman, G.M.; Westenberga, T. Decreased thalamic blood flow in obsessive-compulsive disorder patients responding to fluvoxamine. Psychiatry Res. Neuroimaging, 2005, 138, 89-97. [http://dx.doi.org/ 10.1016/j.pscychresns.2004.12.003].
[35]
Ho Pian, K.L.; van Megen, H.J.; Ramsey, N.F.; Mandl, R.; van Rijk, P.P.; Wynne, H.J.; Westenberg, H.G. Decreased thalamic blood flow in obsessive-compulsive disorder patients responding to fluvoxamine. Psychiatry Res., 2005, 138(2), 89-97. [http://dx.doi. org/10.1016/j.pscychresns.2004.12.003]. [PMID: 15766633].
[36]
Wen, S.L.; Cheng, M.H.; Cheng, M.F.; Yue, J.H.; Wang, H. Pharmacotherapy response and regional cerebral blood flow characteristics in patients with obsessive-compulsive disorder. Behav. Brain Funct., 2013, 30, 9-31. [http://dx.doi.org/10.1186/1744-9081-9-31].
[37]
Shin, D.J.; Jung, W.H.; He, Y.; Wang, J.; Shim, G.; Byun, M.S.; Jang, J.H.; Kim, S.N.; Lee, T.Y.; Park, H.Y.; Kwon, J.S. The effects of pharmacological treatment on functional brain connectome in obsessive-compulsive disorder. Biol. Psychiatry, 2014, 75(8), 606-614. [http://dx.doi.org/10.1016/j.biopsych.2013.09.002]. [PMID: 24099506].


Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 17
ISSUE: 8
Year: 2019
Page: [737 - 740]
Pages: 4
DOI: 10.2174/1570159X16666180613074059
Price: $58

Article Metrics

PDF: 22
HTML: 1